Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease.
3C Viral Proteases
/ antagonists & inhibitors
Acrylamides
/ chemistry
Animals
Antiviral Agents
/ chemistry
Cell Line
Cell Survival
/ drug effects
Cyanoacrylates
/ chemistry
Enterovirus
/ classification
Enterovirus A, Human
/ drug effects
Enterovirus Infections
/ virology
Humans
Molecular Docking Simulation
Protease Inhibitors
/ chemistry
Virus Replication
/ drug effects
EV71
Protease
Reversible covalent inhibitors
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
23
02
2021
revised:
27
04
2021
accepted:
26
05
2021
pubmed:
4
6
2021
medline:
15
12
2021
entrez:
3
6
2021
Statut:
ppublish
Résumé
As one of the principal etiological agents of hand, foot, and mouth disease (HFMD), enterovirus 71 (EV71) is associated with severe neurological complications or fatal diseases, while without effective medications thus far. Here we applied dually activated Michael acceptor to develop a series of reversible covalent compounds for EV71 3C protease (3C
Identifiants
pubmed: 34082057
pii: S0166-3542(21)00092-9
doi: 10.1016/j.antiviral.2021.105102
pii:
doi:
Substances chimiques
Acrylamides
0
Antiviral Agents
0
Cyanoacrylates
0
Protease Inhibitors
0
3C Viral Proteases
EC 3.4.22.28
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105102Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.